References
- Abdelgawad IA, Mossallam GI, Radwan NH, et al (2013). Can glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev, 14, 7345-9. https://doi.org/10.7314/APJCP.2013.14.12.7345
- Ahmad Z, Arshad H, Fatima S, et al (2013). Gastrointestinal, liver and biliary tract pathology: a histopathological and epidemiological perspective from Pakistan with a review of the literature. Asian Pac J Cancer Prev, 14, 6997-7005. https://doi.org/10.7314/APJCP.2013.14.11.6997
- Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9. https://doi.org/10.7314/APJCP.2013.14.12.7367
- Banjerdpongchai R, Wudtiwai B, Sringarm K (2013). Cytotoxic and apoptotic-inducing effects of purple rice extracts and chemotherapeutic drugs on human cancer cell lines. Asian Pac J Cancer Prev, 14, 6541-8. https://doi.org/10.7314/APJCP.2013.14.11.6541
- Chittmittrapap S, Chieochansin T, Chaiteerakij, et al (2013). Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). Asian Pac J Cancer Prev, 14, 7675-9. https://doi.org/10.7314/APJCP.2013.14.12.7675
- Chen HL, Zhou DH (2003). The experience to treat liver cancer. J Traditional Chinese Med, 44, 894-895.
- Caldwell S, Park SH (2009). The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol, 44, 96-101. https://doi.org/10.1007/s00535-008-2258-6
- Chen XL, Wang BQ (2007). Introduction to pixu and the correlation of liver cancer. Trad Chin Med Jilin, 27, 5-7.
- Cheung F, Wang X, Wang N, et al (2013). Chinese medicines as an adjuvant therapy for unresectable hepatocellular carcinoma during transarterial chemoembolization: a Meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med, 2013, 487919.
- Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
- Guo RP, Zhong C, Shi M, et al (2006). Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol, 132, 547-55. https://doi.org/10.1007/s00432-006-0097-5
- Gupta SP, Mittal A, Sathian B, et al (2013). Elevated serum insulin is an independent risk factor for hepatocellular carcinoma: a case control study from Nepal. Asian Pac J Cancer Prev, 14, 7331-3. https://doi.org/10.7314/APJCP.2013.14.12.7331
- Gao FY, Li YF, Zhang AQ (2011). Research progress of traditional Chinese medicine in the treatment of primary liver cancer. China Cancer, 20, 764-767.
- Hao YX, Wang JP, Zhao LF (2013). Associations between three common MicroRNA polymorphisms and hepatocellular carcinoma risk in Chinese. Asian Pac J Cancer Prev, 14, 6601-4 https://doi.org/10.7314/APJCP.2013.14.11.6601
- Hu Y, Chen RS (2008). Treatment of liver cancer experience isintroduced. J New Chinese Med, 40, 12.
- Liu XN, Li N (2012). Primary liver cancer clinical medication meta-analysis of traditional Chinese medicine. China J Chin Mater Med, 37, 1327-31.
- Li GH, Chen MS, Li JQ, et al (2002). The effect of the resection of liver cancer and experience. Chinese J Hepatobiliary Surgery, 8, 190-1.
- Ministry of Health of the People's Republic of China (2011). Primary liver cancer diagnosis and treatment standards (2011 edition), J Clin Oncol, 929-46.
- Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9 https://doi.org/10.7314/APJCP.2013.14.11.6955
- Shi M, Guo RP, Lin XJ, et al (2007). Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg, 245, 36-43. https://doi.org/10.1097/01.sla.0000231758.07868.71
- Sobin LH, Gospodarowicz MK, Wittekind C (2019). International Union Against Cancer (UICC). TNM classification of malignant tumours (7thed)[S]. New York:Wiley-Liss, 80-85.
- Su XK, Ye XW, Lin MQ, et al (2006). Method of 'jian pi hua yu '82 cases of postoperative recurrence of liver cancer clinical research. J Traditional Chinese Med, 47, 673-5.
- Tang ZY (2011). Combine traditional Chinese and western medicine treatment of liver cancer. Combine traditional Chinese and western medicine liver disease 21, 129-30.
- The state food and drug administration. Chinese medicine new medicine clinical research guiding principle (2002). Beijing: China medical science and technology press, kunming, China. 210-2.
- Tian YZ, Li HY, Du HT (2012). Combine traditional chinese and western medicine treatment curative effect of liver cancer research. J Chinese Med, 27, 1246-7.
- Wu MC, Chen H, Shen F (2001). Surgical treatment of primary liver cancer, with 5524 cases report. Chin J Surg, 39, 25-8.
- Yang HL, (2013). The clinical value of w.k.che treated from the spleen liver cancer. J Traditional Chinese Med, 54, 623-4.
- Yu RX (2001). Thinking of the TCM therapy for cancer. tumour, 21, 419-20
- Ye SL, Qin SK, Wu MC, et al (2009). Experts consensus on diagnosis and treatment for primary hepatocellular carcinoma4.29 (4):295-304.
- Zhu WJ, Huang CY, Li C, et al (2013). Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection. Asian Pac J Cancer Prev, 14, 7101-6. https://doi.org/10.7314/APJCP.2013.14.12.7101
- Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, et al (2013). Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev, 14, 6721-6. https://doi.org/10.7314/APJCP.2013.14.11.6721
- Zhang J, Wang R, Ma YY, et al (2013). Association between single nucleotide polymorphisms in miRNA196a-2 and miRNA146a and susceptibility to hepatocellular carcinoma in a Chinese population. Asian Pac J Cancer Prev, 14, 6427-31. https://doi.org/10.7314/APJCP.2013.14.11.6427
- Zhong C, Guo RP, Li JQ, et al (2009). A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol, 135, 1437-45. https://doi.org/10.1007/s00432-009-0588-2
- Zhang XW, Yan XJ, Zhou ZR, et al (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 328, 240-3. https://doi.org/10.1126/science.1183424
- Zhen XT, Lin LZ (2009). Experience in treatment of primary liver cancer is introduced. J New Chin Med, 41, 11-2.
- Zhou XD, Tang ZY, Yang BH, et al (2001). Experience in 1000 cases of small liver cancer resection. Chin J Pract Surg, 21, 41-4.
Cited by
- Hepatoprotective Effects of Curcumin Against Diethyl Nitrosamine Induced Hepatotoxicity in Albino Rats vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.103
- Implications of Sex Hormone Receptor Gene Expression in the Predominance of Hepatocellular Carcinoma in Males: Role of Natural Products vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4949
- Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials vol.2017, pp.1741-4288, 2017, https://doi.org/10.1155/2017/3428253
- A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China vol.17, pp.3, 2018, https://doi.org/10.1177/1534735418775819